Forte Biosciences, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 76.99 USD (Aug 26, 2026, 4:00 PM EDT) · Market cap 1.94B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Forte Biosciences, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for autoimmune and autoimmune-related diseases. The company offers products, such as its lead product candidate FB102, a proprietary molecule with applications for celiac disease, vitiligo, and alopecia areata; and services, including the clinical development and management of its Phase 2 clinical trials. Forte Biosciences, Inc. was incorporated in 2007 and is based in Dallas, Texas. As of August 27, 2026, Forte Biosciences, Inc. operates as a subsidiary of argenx SE.
Details
| Name | Forte Biosciences, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 23 |
| Founded | 2007 |
| Ceo | Paul A. Wagner |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US34962G2084 |
| Cusip | 34962G208 |
| Cik | 1419041 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Dr. Paul A. Wagner Ph.D. | Chief Executive Officer, President and Chairman |
| Antony A. Riley CPA | Chief Financial Officer |
| Dr. Barbara K. Finck M.D. | Senior Medical Clinician and Director |
| Christopher Roenfeldt | Chief Operating Officer |
Contact
| Address | 3060 Pegasus Park Drive, Building 6, Dallas, Texas 75247, United States |
| Phone | 310 618 6994 |
| Website | https://www.fortebiorx.com |